吡格列酮对合并代谢综合征的2型糖尿病患者血清炎症因子及胰岛素抵抗的影响  

Effects of pioglitazone on serum inflammatory factors and insulin resistance of type 2 diabetic patients with metabolic syndrome

作　　者：肖斌[1] 王晓茜[1] 陈雅文[1] 

机构地区：[1]四川省德阳市人民医院内分泌科,四川德阳618000

出　　处：《海南医学院学报》2015年第4期489-491,共3页Journal of Hainan Medical University

基　　金：四川省技术创新资助项目(2013CD00451)~~

摘　　要：目的:探讨吡格列酮对合并代谢综合征的2型糖尿病患者血清炎症因子及胰岛素抵抗的影响。方法:选取合并代谢综合征的2型糖尿病患者90例,按照就诊顺序将其随机分为观察组和对照组,每组各45例。对照组给予二甲双胍等常规口服降糖药物治疗,观察组在对照组的基础上加用吡格列酮进行治疗。两组均连续治疗3个月,测定其治疗前后白介素-6(IL-6)、肿瘤坏死因子α(TNF-α)、超敏C反应蛋白(hs-CRP)、纤溶酶原激活物抑制物-1(PAI-1)、脂联素(ADP)以及空腹血糖(FPG)、餐后2h血糖(2hPG)、空腹胰岛素(FINS)、糖化血红蛋白(HbAlC)等生化指标,并计算胰岛素抵抗指数(HOMAIR)。结果:观察组治疗后IL-6、TNF-α、PAI-1、hs-CRP水平与治疗前比较明显下降(P<0.05),且显著低于对照组治疗后(P<0.05)。观察组治疗后FPG、2hPG、FINS、HbAlC及HOMA-IR均较治疗前明显下降(P<0.05),且显著低于对照组治疗后(P<0.05)。结论:吡格列酮对合并代谢综合征的2型糖尿病有较好的疗效,能够有效降低患者血糖水平,通过调节炎性因子改善胰岛素抵抗,具有较高的临床应用价值,值得大力推广。Objective：To investigate the effects of pioglitazone on serum inflammatory factors and insulin resistance of type 2diabetic patients with metabolic syndrome.Methods：A total of 90 type 2diabetic patients with metabolic syndrome were randomly divided into the observation group and control group,according to the order of treatment by half.Patients in control group were given metformin and other conventional oral hypoglycemic drug treatment,patients in the observation group were treated with pioglitazone plus.Patients in two groups were treated for 3months.The determination of interleukin-6（IL-6）,tumor necrosis factor alpha（TNF-α）,high sensitive C reactive protein（hs-CRP）,plasminogen activator inhibitor-1（PAI-1）,adiponectin（ADP）and fasting blood glucose（FPG）were tested,the blood glucose（2hPG）,fasting insulin（FINS）and glycosylated hemoglobin（HbAlC）and other biochemical indicators postprandial 2hand calculated the insulin resistance index（HOMA-IR）were tested.Results：After treatment,the IL-6,TNF-alpha,PAI-1and hs-CRP levels of observation group decreased significantly compared with before treatment（t=7.64,8.47,8.38,8.27,P〈0.05）,and significantly lower than the control group（t=7.46,8.32,8.26,7.85,P〈0.05）.The FPG,2hPG,FINS,HbAlC and HOMA-IR of observation group after treatment were significantly decreased than before treatment（t=7.84,8.56,8.78,7.97,8.34,P〈0.05）,and significantly lower than the control group（t=8.42,8.39,7.86,8.65,7.92,P〈0.05）.Conclusion：Pioglitazone is effective on on serum inflammatory factors and insulin resistance of type 2diabetic patients with metabolic syndrome.It can effectively reduce the blood glucose levels in patients with inflammatory factors,improve insulin resistance.It has high clinical application value,and it is worth to popularize.

关 键 词：吡格列酮 代谢综合征 糖尿病 

分 类 号：R587.1[医药卫生—内分泌]